LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 41

Search options

  1. Article ; Online: SARS-CoV-2 Antibody Testing: Where Are We Now?

    Smerczak, Elizabeth

    Laboratory medicine

    2021  Volume 53, Issue 2, Page(s) e19–e29

    MeSH term(s) Antibodies, Viral ; COVID-19/diagnosis ; Humans ; SARS-CoV-2
    Chemical Substances Antibodies, Viral
    Language English
    Publishing date 2021-08-18
    Publishing country England
    Document type Journal Article
    ZDB-ID 391758-7
    ISSN 1943-7730 ; 0007-5027
    ISSN (online) 1943-7730
    ISSN 0007-5027
    DOI 10.1093/labmed/lmab061
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Bioconjugated Nanomaterial for Targeted Diagnosis of SARS-CoV-2.

    Pramanik, Avijit / Gao, Ye / Patibandla, Shamily / Gates, Kalein / Ray, Paresh Chandra

    Accounts of materials research

    2022  Volume 3, Issue 2, Page(s) 134–148

    Abstract: ... to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus is responsible for more than 4.8 M death worldwide until now ... of the SARS-CoV-2 virus and the SARS-CoV-2 viral RNA, antigen, or antibody, with a particular focus ... surface energy transfer (NSET)-based on specific identification of SARS-CoV-2 infections via CNT ...

    Abstract Infectious diseases by pathogenic microorganisms are one of the leading causes of mortality worldwide. Healthcare and socio-economic development have been seriously affected for different civilizations because of bacterial and viral infections. According to the Centers for Disease Control and Prevention (CDC), pandemic in 1918 by the Influenza A virus of the H1N1 subtype was responsible for 50 to 100 million deaths worldwide. Similarly, the Asian flu pandemic in 1957, Hong Kong flu in 1968, and H1N1pdm09 flu pandemic in 2009 were responsible for more than 1 million deaths across the globe each time. As per the World Health Organization (WHO), the current pandemic by coronavirus disease 2019 (COVID-19) due to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus is responsible for more than 4.8 M death worldwide until now. Since the gold standard polymerase chain reaction (PCR) test is more time-consuming, the health care system cannot test all symptomatic and asymptomatic Covid patients every day, which is extremely important to tackle the outbreak. One of the significant challenges during the current pandemic is developing mass testing tools, which is critical to control the virus spread in the community. Therefore, it is highly desirable to develop advanced material-based approaches that can provide a rapid and accurate diagnosis of COVID-19, which will have the capability to save millions of human lives. Aiming for the targeted diagnosis of deadly virus, researchers have developed nanomaterials with various sizes, shapes, and dimensions. These nanomaterials have been used to identify biomolecules via unique optical, electrical, magnetic, structural, and functional properties, which are lacking in other materials. Despite significant progress, nanomaterial-based diagnosis of biomolecules is still facing several obstacles due to low targeting efficiency and nonspecific interactions. To overcome these problems, the bioconjugated nanoparticle has been designed via surface coating with polyethylene glycol (PEG) and then conjugated with antibodies, DNA, RNA, or peptide aptamers. Therefore, the current Account summarizes an overview of the recent advances in the design of bioconjugated nanomaterial-based approached as effective diagnosis of the SARS-CoV-2 virus and the SARS-CoV-2 viral RNA, antigen, or antibody, with a particular focus on our work and other's work related to this subject. First, we present how to tailor the surface functionalities of nanomaterials to achieve bioconjugated material for targeted diagnosis of the virus. Then we review the very recent advances in the design of antibody/aptamer/peptide conjugated nanostructure, which represent a powerful platform for naked-eye colorimetric detection via plasmonic nanoparticles. We then discuss nanomaterial-based surface-enhanced Raman scattering (SERS) spectroscopy, which has the capability for very low-level fingerprint identification of virus, antigen, and antibody via graphene, plasmonic nanoparticle, and heterostructure material. After that, we summarized about fluorescence and nanoparticle surface energy transfer (NSET)-based on specific identification of SARS-CoV-2 infections via CNT, quantum dots (QDs), and plasmonic nanoparticles. Finally, we highlight the merit and significant challenges of nanostructure-based tools in infectious diseases diagnosis. For the researchers who want to engage in the new development of bioconjugated material for our survival from the current and future pandemics, we hope that this Account will be helpful for generating ideas that are scientifically stimulating and practically challenging.
    Language English
    Publishing date 2022-01-12
    Publishing country United States
    Document type Journal Article
    ISSN 2643-6728
    ISSN (online) 2643-6728
    DOI 10.1021/accountsmr.1c00177
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Nanotechnology-based theranostic and prophylactic approaches against SARS-CoV-2.

    Dhar, Atika / Gupta, Sneh Lata / Saini, Pratima / Sinha, Kirti / Khandelwal, Ankita / Tyagi, Rohit / Singh, Alka / Sharma, Priyanka / Jaiswal, Rishi Kumar

    Immunologic research

    2023  Volume 72, Issue 1, Page(s) 14–33

    Abstract: SARS-CoV-2 (COVID-19) pandemic has been an unpredicted burden on global healthcare system ... of COVID-19 infection. Therefore, the SARS-CoV-2 outbreak has necessitated the development of specific ... devices for SARS-CoV-2 and the possible applications of nanomaterials in COVID-19 treatment. We also ...

    Abstract SARS-CoV-2 (COVID-19) pandemic has been an unpredicted burden on global healthcare system by infecting over 700 million individuals, with approximately 6 million deaths worldwide. COVID-19 significantly impacted all sectors, but it very adversely affected the healthcare system. These effects were much more evident in the resource limited part of the world. Individuals with acute conditions were also severely impacted. Although classical COVID-19 diagnostics such as RT-PCR and rapid antibody testing have played a crucial role in reducing the spread of infection, these diagnostic techniques are associated with certain limitations. For instance, drawback of RT-PCR diagnostics is that due to degradation of viral RNA during shipping, it can give false negative results. Also, rapid antibody testing majorly depends on the phase of infection and cannot be performed on immune compromised individuals. These limitations in current diagnostic tools require the development of nanodiagnostic tools for early detection of COVID-19 infection. Therefore, the SARS-CoV-2 outbreak has necessitated the development of specific, responsive, accurate, rapid, low-cost, and simple-to-use diagnostic tools at point of care. In recent years, early detection has been a challenge for several health diseases that require prompt attention and treatment. Disease identification at an early stage, increased imaging of inner health issues, and ease of diagnostic processes have all been established using a new discipline of laboratory medicine called nanodiagnostics, even before symptoms have appeared. Nanodiagnostics refers to the application of nanoparticles (material with size equal to or less than 100 nm) for medical diagnostic purposes. The special property of nanomaterials compared to their macroscopic counterparts is a lesser signal loss and an enhanced electromagnetic field. Nanosize of the detection material also enhances its sensitivity and increases the signal to noise ratio. Microchips, nanorobots, biosensors, nanoidentification of single-celled structures, and microelectromechanical systems are some of the most modern nanodiagnostics technologies now in development. Here, we have highlighted the important roles of nanotechnology in healthcare sector, with a detailed focus on the management of the COVID-19 pandemic. We outline the different types of nanotechnology-based diagnostic devices for SARS-CoV-2 and the possible applications of nanomaterials in COVID-19 treatment. We also discuss the utility of nanomaterials in formulating preventive strategies against SARS-CoV-2 including their use in manufacture of protective equipment, formulation of vaccines, and strategies for directly hindering viral infection. We further discuss the factors hindering the large-scale accessibility of nanotechnology-based healthcare applications and suggestions for overcoming them.
    MeSH term(s) Humans ; SARS-CoV-2 ; Precision Medicine ; COVID-19/diagnosis ; COVID-19/prevention & control ; COVID-19 Drug Treatment ; Pandemics/prevention & control ; Nanotechnology
    Language English
    Publishing date 2023-09-08
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 632857-x
    ISSN 1559-0755 ; 0257-277X
    ISSN (online) 1559-0755
    ISSN 0257-277X
    DOI 10.1007/s12026-023-09416-x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Dosing of Convalescent Plasma and Hyperimmune Anti-SARS-CoV-2 Immunoglobulins: A Phase I/II Dose-Finding Study.

    Huygens, Sammy / Preijers, Tim / Swaneveld, Francis H / Kleine Budde, Ilona / GeurtsvanKessel, Corine H / Koch, Birgit C P / Rijnders, Bart J A

    Clinical pharmacokinetics

    2024  Volume 63, Issue 4, Page(s) 497–509

    Abstract: ... Immunocompromised patients, testing negative for anti-SARS-CoV-2 spike antibodies despite vaccination, received a range ... regimens by constructing a population pharmacokinetic (popPK) model describing anti-SARS-CoV-2 antibody ... of anti-SARS-CoV-2 antibodies in the form of COVIg or ConvP infusion. The popPK analysis was performed ...

    Abstract Background and objective: During the COVID-19 pandemic, trials on convalescent plasma (ConvP) were performed without preceding dose-finding studies. This study aimed to assess potential protective dosing regimens by constructing a population pharmacokinetic (popPK) model describing anti-SARS-CoV-2 antibody titers following the administration of ConvP or hyperimmune globulins (COVIg).
    Methods: Immunocompromised patients, testing negative for anti-SARS-CoV-2 spike antibodies despite vaccination, received a range of anti-SARS-CoV-2 antibodies in the form of COVIg or ConvP infusion. The popPK analysis was performed using NONMEM v7.4. Monte Carlo simulations were performed to assess potential COVIg and ConvP dosing regimens for prevention of COVID-19.
    Results: Forty-four patients were enrolled, and data from 42 were used for constructing the popPK model. A two-compartment elimination model with mixed residual error best described the Nab-titers after administration. Inter-individual variation was associated to CL (44.3%), V1 (27.3%), and V2 (29.2%). Lean body weight and type of treatment (ConvP/COVIg) were associated with V1 and V2, respectively. Median elimination half-life was 20 days (interquartile range: 17-25 days). Simulations demonstrated that even monthly infusions of 600 mL of the ConvP or COVIg used in this trial would not achieve potentially protective serum antibody titers for > 90% of the time. However, as a result of hybrid immunity and/or repeated vaccination, plasma donors with extremely high antibody titers are now readily available, and a > 90% target attainment should be possible.
    Conclusion: The results of this study may inform future intervention studies on the prophylactic and therapeutic use of antiviral antibodies in the form of ConvP or COVIg.
    Clinical trial registration number: NL9379 (The Netherlands Trial Register).
    MeSH term(s) Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; Antibodies, Neutralizing/blood ; Antibodies, Neutralizing/immunology ; Antibodies, Neutralizing/administration & dosage ; Antibodies, Viral/blood ; Antibodies, Viral/administration & dosage ; Antibodies, Viral/immunology ; COVID-19/immunology ; COVID-19 Serotherapy ; Immunization, Passive/methods ; Immunocompromised Host ; Models, Biological ; Monte Carlo Method
    Chemical Substances Antibodies, Neutralizing ; Antibodies, Viral
    Language English
    Publishing date 2024-03-01
    Publishing country Switzerland
    Document type Journal Article ; Clinical Trial, Phase I ; Clinical Trial, Phase II ; Research Support, Non-U.S. Gov't
    ZDB-ID 197627-8
    ISSN 1179-1926 ; 0312-5963
    ISSN (online) 1179-1926
    ISSN 0312-5963
    DOI 10.1007/s40262-024-01351-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Diagnostic Testing for SARS-CoV-2 Infection.

    Thomas, Emmanuel / Delabat, Stephanie / Andrews, David M

    Current hepatology reports

    2021  Volume 20, Issue 4, Page(s) 166–174

    Abstract: ... infection with SARS-CoV-2, many options are available to assess infection. Multiple established diagnostic ... related to SARS-CoV-2 virology and antibody responses, that is available to diagnose infection. ... companies are now providing testing platforms whereas initially, testing was being performed with simple PCR ...

    Abstract Purpose of review: Given the rapid development of diagnostic approaches to test for and diagnose infection with SARS-CoV-2, many options are available to assess infection. Multiple established diagnostic companies are now providing testing platforms whereas initially, testing was being performed with simple PCR-based tests using standard laboratory reagents.
    Recent findings: Additional testing platforms continue to be developed but challenges with testing, including obtaining testing reagents and other related supplies, are frequently encountered. With time, the testing supply chain will improve and more companies will be providing materials to support these testing efforts. In the USA, the need for rapid assay development and subsequent approval through attainment of emergency use authorization (EUA) has superseded the traditional arduous diagnostic testing approval workflow mandated by the FDA. It is anticipated that the USA will be able to continue to significantly increase its testing capabilities to address this pandemic; however, challenges remain due to the diversity of the performance characteristics of tests being utilized.
    Summary: This review provides an overview of the current diagnostic testing landscape, with pertinent information related to SARS-CoV-2 virology and antibody responses, that is available to diagnose infection.
    Language English
    Publishing date 2021-10-28
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2813071-6
    ISSN 2195-9595 ; 2195-9595 ; 1540-3416
    ISSN (online) 2195-9595
    ISSN 2195-9595 ; 1540-3416
    DOI 10.1007/s11901-021-00567-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Rare SARS-CoV-2 antibody development in cancer patients.

    Hempel, Louisa / Molnar, Jakob / Robert, Sebastian / Veloso, Julia / Trepotec, Zeljka / Englisch, Sofie / Weinzierl, Philip / Schick, Cordula / Milani, Valeria / Schweneker, Katrin / Fleischmann, Bastian / Scheiber, Josef / Gandorfer, Beate / Kleespies, Axel / Hempel, Dirk / Riedmann, Kristina / Piehler, Armin

    Seminars in oncology

    2021  Volume 48, Issue 2, Page(s) 160–165

    Abstract: ... Until now, it has been assumed that patients who are infected with SARS-CoV-2 will develop antibodies as has ... SARS-CoV-2 antibody development and immunity will be crucial for the further course of the pandemic ... Extraction Kit) and Roche (Elecsys Anti-SARS-CoV-2 immunoassay) were used, respectively, according ...

    Abstract SARS-CoV-2 antibody development and immunity will be crucial for the further course of the pandemic. Until now, it has been assumed that patients who are infected with SARS-CoV-2 will develop antibodies as has been the case with other coronaviruses, like MERS-CoV and SARS-CoV. In the present study, we analyzed the development of antibodies in 77 patients with an oncologic diagnosis 26 days after positive RT-qPCR testing for SARS-CoV2. RT-qPCR and anti-SARS-CoV2-antibody methods from BGI (MGIEasy Magnetic Beads Virus DNA/RNA Extraction Kit) and Roche (Elecsys Anti-SARS-CoV-2 immunoassay) were used, respectively, according to the manufacturers' specifications. Surprisingly, antibody development was detected in only 6 of 77 individuals with a confirmed history of COVID-19. Despite multiple testing, the remaining patients did not show measurable antibody concentrations in subsequent tests. These results undermine the previous hypothesis that SARS-CoV2 infections are regularly associated with antibody development and cast doubt on the provided immunity to COVID-19. Understanding the adaptive and humoral response to SARS-CoV2 will play a key role in vaccine development and gaining further knowledge on the pathogenesis.
    MeSH term(s) Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Viral/blood ; Antibodies, Viral/immunology ; COVID-19/complications ; COVID-19/transmission ; COVID-19/virology ; Child ; Child, Preschool ; Female ; Germany/epidemiology ; Humans ; Infant ; Infant, Newborn ; Male ; Middle Aged ; Neoplasms/blood ; Neoplasms/epidemiology ; Neoplasms/immunology ; Neoplasms/virology ; RNA, Viral/blood ; RNA, Viral/genetics ; SARS-CoV-2/genetics ; SARS-CoV-2/isolation & purification ; Young Adult
    Chemical Substances Antibodies, Viral ; RNA, Viral
    Language English
    Publishing date 2021-01-02
    Publishing country United States
    Document type Journal Article
    ZDB-ID 189220-4
    ISSN 1532-8708 ; 0093-7754
    ISSN (online) 1532-8708
    ISSN 0093-7754
    DOI 10.1053/j.seminoncol.2020.12.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: The Utility of Specific Antibodies Against SARS-CoV-2 in Laboratory Diagnosis.

    Fu, Yu / Pan, Yunbao / Li, Zhiqiang / Li, Yirong

    Frontiers in microbiology

    2021  Volume 11, Page(s) 603058

    Abstract: ... about the antibody responses against SARS-CoV-2 and the clinical utility of serological testing are increasing. It's well ... 2 (SARS-CoV-2) has now become a global pandemic due to its high transmissibility. The unavoidable ... against SARS-CoV-2 as well as neutralizing antibodies and discuss the clinical utility and limitations ...

    Abstract The Coronavirus Disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has now become a global pandemic due to its high transmissibility. The unavoidable shortcomings of traditional diagnostic assay, including nucleic acid testing, diverse serological assays characterized by high-throughput and less workload, are playing a more and more crucial role to supplement the nucleic acid test. In this review, we summarize the dynamic change of the specific IgM, IgG, and IgA antibodies against SARS-CoV-2 as well as neutralizing antibodies and discuss the clinical utility and limitations of the different serological assays. SARS-CoV-2, a newly discovered virus, shows some unique pathogenetic and epidemiological characteristics that have not been completely understood so far. Currently, studies about the antibody responses against SARS-CoV-2 and the clinical utility of serological testing are increasing. It's well suggested that the combination of serological tests and nucleic acid tests can cohesively improve the testing efficiency for identifying COVID-19 suspected patients.
    Language English
    Publishing date 2021-01-13
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2587354-4
    ISSN 1664-302X
    ISSN 1664-302X
    DOI 10.3389/fmicb.2020.603058
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Serological Assays for Assessing Postvaccination SARS-CoV-2 Antibody Response.

    Mahmoud, Sally A / Ganesan, Subhashini / Naik, Shivaraj / Bissar, Safaa / Zamel, Isra Al / Warren, K N / Zaher, Walid A / Khan, Gulfaraz

    Microbiology spectrum

    2021  Volume 9, Issue 2, Page(s) e0073321

    Abstract: Serological assays for measuring severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 ... six commercially available serological assays for detecting SARS-CoV-2 antibodies: (i) Genscript cPass ... surrogate virus neutralization test (Genscript cPass), (ii) Diasorin-SARS-CoV-2 S1/S2 IgG detection ...

    Abstract Serological assays for measuring severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies have crucial applications in the control and surveillance of the current COVID-19 pandemic. A large number of such assays have been developed and are now commercially available. However, there are limited studies evaluating the performance of these tests. We evaluated the performances of the following six commercially available serological assays for detecting SARS-CoV-2 antibodies: (i) Genscript cPass surrogate virus neutralization test (Genscript cPass), (ii) Diasorin-SARS-CoV-2 S1/S2 IgG detection (Diasorin-S1/S2 IgG), (iii) Alinity SARS-CoV-2 IgG II (Alinity IgG II), (iv) Diasorin-SARS-CoV-2 TrimericS IgG (Diasorin-TrimericS IgG), (v) Roche Elecsys anti-SARS-CoV-2-cobas (Roche Elecsys), and (vi) AESKU enzyme linked immunosorbent assay (AESKULISA). The results of these tests were compared against the gold standard plaque reduction neutralization test (PRNT). Roche Elecsys had the highest sensitivity, and the Genscript cPass had the highest specificity. Diasorin-TrimericS IgG had the best overall performance with the highest agreement with the PRNT results. Parallel testing of Genscript cPass with Diasorin-TrimericS IgG and Diasorin-S1/S2 IgG had the optimum performance. Based on the receiver operating characteristic (ROC) curve, lowering the cutoff from 30% to 20% in the Genscript cPass significantly increased the sensitivity and the overall agreement with the PRNT results. Commercially available serological assays are good alternatives to the standard PRNT. However, further studies on larger sample numbers are required for optimization of the assay cutoff values and for evaluation of cost effectiveness.
    MeSH term(s) Adolescent ; Adult ; Aged ; Antibodies, Viral/blood ; COVID-19/immunology ; COVID-19/prevention & control ; COVID-19 Serological Testing/methods ; COVID-19 Vaccines/immunology ; Coronavirus Nucleocapsid Proteins/immunology ; Enzyme-Linked Immunosorbent Assay ; Female ; Humans ; Male ; Middle Aged ; Phosphoproteins/immunology ; SARS-CoV-2/immunology ; Spike Glycoprotein, Coronavirus/immunology ; Vaccines, Inactivated/immunology ; Young Adult
    Chemical Substances Antibodies, Viral ; COVID-19 Vaccines ; Coronavirus Nucleocapsid Proteins ; Phosphoproteins ; Spike Glycoprotein, Coronavirus ; Vaccines, Inactivated ; nucleocapsid phosphoprotein, SARS-CoV-2 ; spike protein, SARS-CoV-2
    Language English
    Publishing date 2021-09-29
    Publishing country United States
    Document type Evaluation Study ; Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 2165-0497
    ISSN (online) 2165-0497
    DOI 10.1128/Spectrum.00733-21
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Conventional and Nanotechnology-Based Sensing Methods for SARS Coronavirus (2019-nCoV).

    Shetti, Nagaraj P / Mishra, Amit / Bukkitgar, Shikandar D / Basu, Soumen / Narang, Jagriti / Raghava Reddy, Kakarla / Aminabhavi, Tejraj M

    ACS applied bio materials

    2021  Volume 4, Issue 2, Page(s) 1178–1190

    Abstract: ... of the infected cases, and maintaining physical and social distances. Numerous methods are now available or being ... available for the general public. The only option available now is by vigorous testing, isolation ... 1,906,853 deaths reported by Jan. 8, 2021. At present, vaccines are being developed in Europe ...

    Abstract Ongoing pandemic coronavirus (COVID-19) has affected over 218 countries and infected 88,512,243 and 1,906,853 deaths reported by Jan. 8, 2021. At present, vaccines are being developed in Europe, Russia, USA, and China, although some of these are in phase III of trials, which are waiting to be available for the general public. The only option available now is by vigorous testing, isolation of the infected cases, and maintaining physical and social distances. Numerous methods are now available or being developed for testing the suspected cases, which may act as carriers of the virus. In this review, efforts have been made to discuss the conventional as well as fast, rapid, and efficient testing methods developed for the diagnosis of 2019-nCoV.Testing methods can be based on the sensing of targets, which include RNA, spike proteins and antibodies such as IgG and IgM. Apart from the development of RNA targeted PCR, antibody and VSV pseudovirus neutralization assay along with several other diagnostic techniques have been developed. Additionally, nanotechnology-based sensors are being developed for the diagnosis of the virus, and these are also discussed.
    MeSH term(s) Animals ; Antibodies, Immobilized/immunology ; Antibodies, Neutralizing/analysis ; Antibodies, Neutralizing/immunology ; Antibodies, Viral/immunology ; Biosensing Techniques/methods ; COVID-19/diagnosis ; Graphite/chemistry ; Humans ; Metal Nanoparticles/chemistry ; Nanotechnology/methods ; SARS-CoV-2/chemistry ; SARS-CoV-2/immunology ; Spike Glycoprotein, Coronavirus/analysis ; Spike Glycoprotein, Coronavirus/immunology
    Chemical Substances Antibodies, Immobilized ; Antibodies, Neutralizing ; Antibodies, Viral ; Spike Glycoprotein, Coronavirus ; spike protein, SARS-CoV-2 ; Graphite (7782-42-5)
    Language English
    Publishing date 2021-02-04
    Publishing country United States
    Document type Journal Article ; Review
    ISSN 2576-6422
    ISSN (online) 2576-6422
    DOI 10.1021/acsabm.0c01545
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey.

    van Doesum, Jaap A / Salmanton-García, Jon / Marchesi, Francesco / Di Blasi, Roberta / Falces-Romero, Iker / Cabirta, Alba / Farina, Francesca / Besson, Caroline / Weinbergerová, Barbora / Van Praet, Jens / Schönlein, Martin / López-García, Alberto / Lamure, Sylvain / Guidetti, Anna / De Ramón-Sánchez, Cristina / Batinić, Josip / Gavriilaki, Eleni / Tragiannidis, Athanasios / Tisi, Maria Chiara /
    Plantefeve, Gaëtan / Petzer, Verena / Ormazabal-Vélez, Irati / Marques de Almeida, Joyce / Marchetti, Monia / Maertens, Johan / Machado, Marina / Kulasekararaj, Austin / Hernández-Rivas, José-Ángel / Gomes da Silva, Maria / Fernández, Noemí / Espigado, Ildefonso / Drgoňa, Ľuboš / Dragonetti, Giulia / Metafuni, Elisabetta / Calbacho, Maria / Blennow, Ola / Wolf, Dominik / van Anrooij, Bjorn / Nunes Rodrigues, Raquel / Nordlander, Anna / Martín-González, Juan-Alberto / Liévin, Raphaël / Jiménez, Moraima / Gräfe, Stefanie K / García-Sanz, Ramón / Córdoba, Raúl / Rahimli, Laman / van Meerten, Tom / Cornely, Oliver A / Pagano, Livio

    Blood advances

    2023  Volume 7, Issue 11, Page(s) 2645–2655

    Abstract: ... previously been shown to cause high mortality in this population. Until now, real-world data on the impact ... of vaccination and treatment on patients with COVID-19 after CD19-directed CAR T-cell therapy are lacking ... 2% [P = .379]). In addition, the course of the disease appears milder with less frequent ...

    Abstract Patients with previous CD19-directed chimeric antigen receptor (CAR) T-cell therapy have a prolonged vulnerability to viral infections. Coronavirus disease 2019 (COVID-19) has a great impact and has previously been shown to cause high mortality in this population. Until now, real-world data on the impact of vaccination and treatment on patients with COVID-19 after CD19-directed CAR T-cell therapy are lacking. Therefore, this multicenter, retrospective study was conducted with data from the EPICOVIDEHA survey. Sixty-four patients were identified. The overall mortality caused by COVID-19 was 31%. Patients infected with the Omicron variant had a significantly lower risk of death due to COVID-19 compared with patients infected with previous variants (7% vs 58% [P = .012]). Twenty-six patients were vaccinated at the time of the COVID-19 diagnosis. Two vaccinations showed a marked but unsignificant reduction in the risk of COVID-19-caused mortality (33.3% vs 14.2% [P = .379]). In addition, the course of the disease appears milder with less frequent intensive care unit admissions (39% vs 14% [P = .054]) and a shorter duration of hospitalization (7 vs 27.5 days [P = .022]). Of the available treatment options, only monoclonal antibodies seemed to be effective at reducing mortality from 32% to 0% (P = .036). We conclude that survival rates of CAR T-cell recipients with COVID-19 improved over time and that the combination of prior vaccination and monoclonal antibody treatment significantly reduces their risk of death. This trial was registered at www.clinicaltrials.gov as #NCT04733729.
    MeSH term(s) Humans ; COVID-19/therapy ; COVID-19 Testing ; COVID-19 Vaccines ; Immunotherapy, Adoptive ; Retrospective Studies ; SARS-CoV-2 ; Vaccination ; Adaptor Proteins, Signal Transducing ; Antibodies, Monoclonal ; Antigens, CD19
    Chemical Substances COVID-19 Vaccines ; Adaptor Proteins, Signal Transducing ; Antibodies, Monoclonal ; Antigens, CD19
    Language English
    Publishing date 2023-04-14
    Publishing country United States
    Document type Multicenter Study ; Journal Article
    ZDB-ID 2915908-8
    ISSN 2473-9537 ; 2473-9529
    ISSN (online) 2473-9537
    ISSN 2473-9529
    DOI 10.1182/bloodadvances.2022009578
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top